Treatment with ponatinib in combination with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), alternating with high-dose methotrexate and cytarabine, resulted in excellent 2-year EFS in adults with newly diagnosed BCR/ABL1-positive ALL [45]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.